Recently, an increasing number of cases with delayed cutaneous reaction after immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. This adverse reaction, which is considered a delayed-type or T cell-mediated hypersensitivity reaction, has been described for the Moderna (mRNA-1273) and Comirnaty (Pfizer/BioNTech, BNT162b2) vaccines. We describe a delayed large local cutaneous reaction in a patient who received the viral vector vaccine Vaxzevria (ChAdOx1-S, AstraZeneca). The time course and clinical symptoms of delayed skin reaction after mRNA vaccines have a similar pattern that we recognized in our patient after Vaxzevria vaccination. This phenomenon has not been described in the Vaxzevria clinical trials and is to our knowledge the first report of this adverse reaction to a vector-based SARS-CoV-2 vaccine. With this, we hope to raise awareness about delayed injection site reactions that also occur after viral vector vaccines and to encourage additional reporting and patient education regarding the cutaneous reactions after coronavirus disease 2019 (COVID-19) vaccination.

最近，越来越多的病例报告了使用基于 mRNA 的针对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的疫苗进行免疫后出现延迟性皮肤反应的病例。这种不良反应被认为是延迟型或 T 细胞介导的超敏反应，已在 Moderna (mRNA-1273) 和 Comirnaty (Pfizer/BioNTech, BNT162b2) 疫苗中进行了描述。我们描述了接受病毒载体疫苗 Vaxzevria（ChAdOx1-S，阿斯利康）的患者的延迟大局部皮肤反应。mRNA 疫苗后延迟性皮肤反应的时间进程和临床症状与我们在 Vaxzevria 疫苗接种后在我们的患者身上发现的模式相似。Vaxzevria 临床试验中尚未描述这种现象，据我们所知，这是对基于载体的 SARS-CoV-2 疫苗的这种不良反应的第一份报告。借此，我们希望提高对病毒载体疫苗接种后也会发生的延迟注射部位反应的认识，并鼓励关于 2019 年冠状病毒病 (COVID-19) 疫苗接种后皮肤反应的额外报告和患者教育。